An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib and Nivolumab in Patients With Unresectable or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Nivolumab (Primary) ; Rivoceranib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors LSK Biopharma
- 28 Dec 2017 New trial record
- 27 Dec 2017 According to a LSK Biopharma media release, first patient has been enrolled in the study. The study is taking place at the Cancer Center of Southern California (CCSC) under the direction of Dr. Sant P. Chawla.
- 27 Dec 2017 Status changed from planning to recruiting, according to a LSK Biopharma media release.